Brokers Offer Predictions for ACRV FY2030 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – HC Wainwright issued their FY2030 earnings estimates for shares of Acrivon Therapeutics in a note issued to investors on Friday, February 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.08) for the year. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

Several other equities research analysts have also recently commented on ACRV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Piper Sandler boosted their price target on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Stock Down 17.9%

Acrivon Therapeutics stock opened at $1.51 on Monday. The company has a 50 day moving average of $1.94 and a 200-day moving average of $1.92. Acrivon Therapeutics has a twelve month low of $1.05 and a twelve month high of $5.75. The stock has a market capitalization of $47.66 million, a PE ratio of -0.71 and a beta of 1.79.

Institutional Investors Weigh In On Acrivon Therapeutics

Several large investors have recently made changes to their positions in the stock. Vermillion & White Wealth Management Group LLC acquired a new position in Acrivon Therapeutics during the fourth quarter worth $44,000. Quadrature Capital Ltd bought a new position in shares of Acrivon Therapeutics in the 4th quarter valued at about $50,000. Bridgeway Capital Management LLC grew its position in shares of Acrivon Therapeutics by 87.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $103,000 after acquiring an additional 20,000 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Acrivon Therapeutics during the fourth quarter worth approximately $40,000. Finally, Marshall Wace LLP lifted its position in shares of Acrivon Therapeutics by 231.4% in the fourth quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock valued at $1,196,000 after buying an additional 346,366 shares during the last quarter. Institutional investors and hedge funds own 71.62% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Peter Blume-Jensen purchased 49,000 shares of the stock in a transaction on Wednesday, January 14th. The shares were purchased at an average price of $1.68 per share, with a total value of $82,320.00. Following the transaction, the chief executive officer directly owned 2,095,771 shares of the company’s stock, valued at $3,520,895.28. This trade represents a 2.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders purchased 67,832 shares of company stock valued at $114,534 in the last ninety days. 8.50% of the stock is owned by company insiders.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.